We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




First-Ever Blood Test Detects Parkinson’s Disease

By LabMedica International staff writers
Posted on 24 Jun 2022

Until now, the diagnosis of Parkinson's disease has been based primarily on typical movement disorders such as muscle stiffness, slower movements and shaking. More...

However, the disease starts up to 20 years before it becomes noticeable as a result of these symptoms. To date, there have been neither blood parameters nor imaging examinations to produce a definite diagnosis, let alone early recognition. Scientists around the world are looking for reliable clinically applicable biomarkers for this chronic progressive brain disease. Now, researchers have developed a method that reliably detects protein changes in blood that are typical of Parkinson's disease.

A research team at the Faculty of Medicine at Kiel University (‎Schleswig-Holstein‎, Germany) has developed a biochemical blood-based test for the diagnosis of Parkinson's disease. In a study, the test was able to distinguish the 30 Parkinson’s patients from the 50 control individuals with a very high degree of sensitivity. However, it is still no known whether early stages of the diseases can also be detected and whether the test will work for diseases that are similar to Parkinson’s.

The new method is based on three steps. The first step was to isolate the vesicles of nerve cells in the blood sample. Vesicles are small blisters that are pinched off cells and contain the protein of the original cell. The second step was to look specifically for the protein that causes the disease in these isolated nerve cell vesicles. This is a changed form of α-synuclein. This pathogenic form of α-synuclein can be detected through structure-specific antibodies. The third and most significant step of the detection method involves reproducing these misfolded α-synuclein forms of Parkinson’s patients from vesicles taken from patients’ blood.

“We developed a biochemical blood-based test for the diagnosis of Parkinson's disease. With our procedure, we were able to distinguish the 30 Parkinson’s patients from the 50 control individuals with a very high degree of sensitivity,” said Dr. Annika Kluge from the Faculty of Medicine at Kiel University. “The results are really sensational. They form the basis on which a blood test for diagnosing Parkinson's disease can be developed.”

Related Links:
Kiel University 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Gold Member
Platelet Function Analyzer
PL-12
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.